Newly developed retatrutide, a twin -action medication targeting equally GLP-1 and GIP receptors, is sparking considerable buzz within the weight loss community. Early clinical research have shown impressive reductions in overall size and improvements in metabolic markers for people with excess weight . Experts believe this unique approach may mar